No Data
SymbolStock Name
PriceChg% ChgVolumeTurnoverOpenPre CloseHighLowMarket CapFloat CapSharesShs Float5D % Chg10D % Chg20D % Chg60D % Chg120D % Chg250D % Chg% Year-to-dateDiv YieldTTMTurnover RatioP/E (TTM)P/E (Static)AmplitudeIndustry
Watchlist
CN Stock MarketDetailed Quotes
688289 Sansure Biotech Inc.
- 21.85
- -0.60-2.67%
Trading Dec 23 13:45 CST
12.73BMarket Cap49.10P/E (TTM)
22.59High21.82Low54.23KlotVolume22.45Open22.45Pre Close119.74MTurnover0.93%Turnover Ratio34.96P/E (Static)582.39MShares25.5852wk High1.76P/B12.73BFloat Cap15.6452wk Low26.94Limit Up582.39MShs Float102.24Historical High17.96Limit Down3.43%Amplitude14.02Historical Low0.71Dividend TTM22.08Avg Price33.36KlotAsk3.26%Div YieldTTM100Lot Size19.61KlotBid
Intraday
- 5D
- Daily
- Weekly
- Monthly
- 1Q
- 1Y
Trade Overview
Unit: --
Capital Trend
IntradayDayWeekMonth
No Data
News
Sansure Biotech Inc. (688289.SH): Granted 1.2412 million restricted stocks to 56 incentive recipients.
On December 16th, Gelonghui reports that Sansure Biotech Inc. (688289.SH) announced that on December 16, 2024, it will hold the second Board of Directors' tenth temporary meeting and the second Supervisory Board's seventh temporary meeting in 2024. The meeting will review and approve the proposal regarding the granting of reserved restricted stocks to the incentive targets of the second phase of the 2023 restricted stock incentive plan, establishing December 16, 2024, as the reserved grant date, with a grant price of 8.55 yuan per share for 1.2412 million shares to 56 incentive targets.
Express News | Sansure biotech inc.: The product for detecting the nucleic acid of human adenovirus has obtained the medical instruments registration certificate.
Former Alibaba CEO Wei Zhe joins sansure biotech inc. Latest response: will not involve business related to mergers and acquisitions by Sanshong.
①Wei Zhe expressed that the reason for joining sansure biotech inc. was to deeply empower the medical industry and gain in-depth understanding of the medical industry; ②He recently posted on his Moments saying that his ideas are highly consistent with sansure biotech inc. and the company's director and general manager, and he will deeply cultivate the sinking medical system and layout the blueprint for going global; ③At the end of last year, Wei Zhe and his founded Jia Yu Capital began to get involved in the medical health field, and announced the establishment of Jia Yu-Ziniu Medical Fund with Ziniu Fund.
Sansure Biotech Inc. (688289.SH) has added Xiao Yu and Long Fengying as core technical personnel.
Sansure Biotech Inc. (688289.SH) announced that the company's director, vice president, and chief technical officer Fan Xu, as well as the core technical...
Sansure Biotech Gets EU Approval for Diagnostic Kits, Cell Transport Fluid
Express News | Sansure Biotech Inc.: Related testing products have obtained EU CE certification
